Corporate News

INMUNOTEK at the EAACI congress

June 2019

INMUNOTEK has been present at the EAACI congress held in Lisbon in the commercial exhibition area. The annual conference of the EAACI (European Academy of Allergy and Clinical Immunology) is one of the most important events in the field of allergy and immunology worldwide. With a participation of more than 7,000 delegates and a high scientific and commercial level, the annual congress is the most outstanding event of the EAACI.
More info

Visit of the Regional Minister of Health

Comunidad MadridMarch 2019

The Regional Minister of Health of the Community of Madrid, Enrique Ruiz Escudero, has visited INMUNOTEK after receiving the CEIM award as the best innovative company. The visit was accompanied by Luisa María Fernanda, General Director of Madrid Activa. After a presentation of the company by José Luis Subiza, CEO-President of INMUNOTEK, a visit was made to the production facilities and the R&D laboratories.
More info

INMUNOTEK revalidates its Innovative SME stamp

March 2019

INMUNOTEK revalidates its Innovative SME stamp issued by the Spanish Government at the Directorate General for Innovation and Competitiveness of the Ministry of Economy. This stamp was granted to INMUNOTEK in 2015.
More info

INMUNOTEK best innovative company

Premios CEIM InmunotekOctober 2018

INMUNOTEK is awarded as Best Innovative Company and distinguished as one of the three companies with the largest International Expansion, in the first edition of the CEIM-CEOE Awards. This recognition is given to companies that have stood out, both for their contribution to economic development, the creation of employment and for their work at the service of the community. Javier Ruiz, Deputy Minister of Economy and Competitiveness of the Community of Madrid has been in charge of giving the award to Dr. Enrique Fernández Caldas, Scientific Director of INMUNOTEK.
More info

RETOS-COLABORACION 2017 Grant

MinisterioSeptember 2018

The Spanish Ministry of Science, Innovation and Universities has granted the funding of a research project for the development of a new biomarker in prostate cancer. The application was submitted by INMUNOTEK together with the ICSCYL Foundation to Retos-Colaboracion 2017 grant program.
More info